Literature DB >> 32555033

NUT Carcinoma Without Upfront Surgical Resection: A Case Report.

Rachel Leeman1, Kerice Pinkney2, Julie A Bradley3, Robert Ruiz4, Steven G DuBois5, Christopher French6, Matteo Trucco7.   

Abstract

Nuclear protein in testis carcinoma is a rare and highly aggressive carcinoma associated with a 70% mortality rate 1 year from diagnosis and a median survival of only 6.5 months. No established treatment protocol exists, although some success has been achieved using a multimodal approach including early surgical resection and adjuvant chemotherapy and radiation. Prior studies have not demonstrated successful treatment in the absence of upfront surgical resection. We describe the first reported case of a patient with unresectable nuclear protein in testis carcinoma treated successfully with definitive chemotherapy using the Scandinavian Sarcoma Group IX Protocol and concurrent radiation therapy, but without surgical resection.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32555033      PMCID: PMC8887700          DOI: 10.1097/MPH.0000000000001865

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.170


  18 in total

1.  Successful treatment of a child with t(15;19)-positive tumor.

Authors:  Fredrik Mertens; Thomas Wiebe; Catharina Adlercreutz; Nils Mandahl; Christopher A French
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

2.  Clinicopathologic features and long-term outcomes of NUT midline carcinoma.

Authors:  Daniel E Bauer; Chelsey M Mitchell; Kelly M Strait; Christopher S Lathan; Edward B Stelow; Sonja C Lüer; Somala Muhammed; Andrew G Evans; Lynette M Sholl; Juan Rosai; Eugenia Giraldi; Richard P Oakley; Carlos Rodriguez-Galindo; Wendy B London; Stephen E Sallan; James E Bradner; Christopher A French
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

3.  Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach.

Authors:  Simone Storck; Alyssa L Kennedy; Karen J Marcus; Lisa Teot; Jennifer Vaughn; Astrid K Gnekow; Bruno Märkl; Ivo Leuschner; Steven G DuBois; Christopher A French; Michael C Frühwald
Journal:  Pediatr Hematol Oncol       Date:  2017-10-17       Impact factor: 1.969

Review 4.  NUT midline carcinoma.

Authors:  Christopher Alexander French
Journal:  Cancer Genet Cytogenet       Date:  2010-11

5.  NUT carcinoma in children and adults: A multicenter retrospective study.

Authors:  Lauriane Lemelle; Gaëlle Pierron; Paul Fréneaux; Sophie Huybrechts; Alexandra Spiegel; Dominique Plantaz; Morbize Julieron; Sophie Dumoucel; Antoine Italiano; Fréderic Millot; Christophe Le Tourneau; Guy Leverger; Pascal Chastagner; Matthieu Carton; Daniel Orbach
Journal:  Pediatr Blood Cancer       Date:  2017-06-23       Impact factor: 3.167

6.  Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.

Authors:  Anastasios Stathis; Emanuele Zucca; Mohamed Bekradda; Carlos Gomez-Roca; Jean-Pierre Delord; Thibault de La Motte Rouge; Emmanuelle Uro-Coste; Filippo de Braud; Giuseppe Pelosi; Christopher A French
Journal:  Cancer Discov       Date:  2016-03-14       Impact factor: 39.397

7.  Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.

Authors:  Nicole G Chau; Shelley Hurwitz; Chelsey M Mitchell; Alexandra Aserlind; Noam Grunfeld; Leah Kaplan; Peter Hsi; Daniel E Bauer; Christopher S Lathan; Carlos Rodriguez-Galindo; Roy B Tishler; Robert I Haddad; Stephen E Sallan; James E Bradner; Christopher A French
Journal:  Cancer       Date:  2016-08-10       Impact factor: 6.860

Review 8.  NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.

Authors:  Christopher A French
Journal:  Pathol Int       Date:  2018-10-26       Impact factor: 2.534

9.  Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.

Authors:  J-K Lee; S Louzada; Y An; S Y Kim; S Kim; J Youk; S Park; S H Koo; B Keam; Y K Jeon; J-L Ku; F Yang; T M Kim; Y S Ju
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

10.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

View more
  3 in total

1.  Report of the First International Symposium on NUT Carcinoma.

Authors:  Christopher A French; Michael L Cheng; Glenn J Hanna; Steven G DuBois; Nicole G Chau; Christine L Hann; Simone Storck; Ravi Salgia; Matteo Trucco; Jennifer Tseng; Anastasios Stathis; Richard Piekarz; Ulrich M Lauer; Christophe Massard; Kelly Bennett; Shodeinde Coker; Ulrike Tontsch-Grunt; Martin L Sos; Sida Liao; Catherine J Wu; Kornelia Polyak; Sarina A Piha-Paul; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2022-06-13       Impact factor: 13.801

2.  Complete Response Induced by Concurrent Chemoradiotherapy in a Patient with NUT Carcinoma.

Authors:  Joji Muramatsu; Kohichi Takada; Shintaro Sugita; Takaaki Tsuchiya; Keisuke Yamamoto; Masaru Takagi; Kazuyuki Murase; Saki Ameda; Yohei Arihara; Koji Miyanishi; Koh-Ichi Sakata; Junji Kato
Journal:  Intern Med       Date:  2021-10-05       Impact factor: 1.282

Review 3.  NUT Carcinoma-An Underdiagnosed Malignancy.

Authors:  Ulrich M Lauer; Martina Hinterleitner; Marius Horger; Paul V Ohnesorge; Lars Zender
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.